Personalized melanoma vaccine extends cancer-free period in trial
Moderna's personalised melanoma vaccine, given with Keytruda, kept high-risk patients cancer-free longer in interim stage 3 trial results, but full data is pending.
The Full Story
A plain summary built from the channels that reported this story.
A personalised vaccine for melanoma, the most serious form of skin cancer, has shown encouraging results in a late-stage clinical trial, extending the time patients stayed cancer-free after surgery.
The vaccine, made by the biotechnology company Moderna, is tailored to each patient's tumour and is given alongside an existing drug called Keytruda, made by Merck. In the trial, patients with high-risk melanoma who had already had surgery to remove their tumour were either given the vaccine plus Keytruda, or Keytruda alone.
The results showed that those who received the combination had a significantly longer period before the cancer came back, and a reduced risk of it spreading to other organs, compared with those who had only the drug.
The findings are still interim, from a stage 3 trial, which is the final stage before a treatment can be approved for wider use. The full data has not yet been released, and some researchers have urged caution. Cancer Research UK said the results were 'showing signs of early positive encouragement'.
Despite that caution, the news has been greeted with optimism, and a sharp rise in the share prices of both Moderna and Merck, which makes Keytruda. One commentator described the results as a 'breakthrough', suggesting that vaccines could one day be used to protect against the recurrence of a cancer that is often fatal.
The trial is part of a broader push towards personalised medicine, where treatments are tailored to the genetic makeup of a patient's tumour. The vaccine is designed to train the immune system to recognise and attack the specific mutations in a patient's cancer cells.
Further studies and more complete data will be needed before the approach could become a standard treatment. But for now, the results offer a measure of hope for people facing one of the most aggressive forms of skin cancer.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Key Claims
Claims reported during this story's coverage, mapped by channel. Ordered by how many channels carried each claim.
| Claim | BBC News | BBC One |
|---|---|---|
| A personalised Moderna vaccine is given after surgery with Merck's Keytruda. | ||
| The trial showed longer cancer-free survival and reduced risk of spread for high-risk melanoma patients. | ||
| Share prices for Moderna and Merck rose after the announcement. | · | |
| The vaccine trial is at stage 3, the final phase, and the findings are interim. | · |
Channel Perspectives
What each channel focused on, with key quotes.
This bulletin presented the story as one part of a wider news hour, with a cautious tone. The presenter and reporter Hugh Pym stressed that the findings were preliminary and that some commentators were holding back, while noting Cancer Research UK's cautious but optimistic reaction.
- “Well Clive it's looking that way but these are interim findings from this stage 3 trial”
- “Cancer Research UK says it is showing signs of early positive Encouragement”
- “a breakthrough showing a vaccine Can protect against the recurrence of one of the deadliest cancers”
The signed bulletin presented the same core information as the West bulletin, using identical phrasing and pace. The tone was balanced, with the anchor describing the news as 'encouraging' while the health editor repeated the caveat about interim data.
- “Well, Clive, it's looking that way, but these are interim findings from this stage three trial”
- “It's seen as significant because it's a personalised treatment, and one commentator has said this is a breakthrough showing a vaccine can protect against the recurrence of one of the deadliest cancers”
This bulletin opened with a murder inquiry and then moved to the vaccine story with a more upbeat framing, using the word 'optimistic' at the outset. It also included the stock market reaction, mentioning that share prices for both companies rose on Wall Street, and omitted the broader context about other cancer studies that appeared in the other bulletins.
- “this is Optimistic news here”
- “this is a personalized vaccine for individual patients”
- “That hasn't stopped the investable prices going up pretty significantly for both companies on Wall Street tonight”
Broadcast Timeline
News broadcasts tracked for this story, in time order.